Business Wire

IDEMIA

13.7.2021 12:48:11 CEST | Business Wire | Press release

Share
IDEMIA Announces a Global Partnership With Bosch Building Technologies to Tap the $1bn Biometric Access Control Market

IDEMIA, the leader of Augmented Identity announced today a global partnership with Bosch Building Technologies, a global leader in the security market, to tap the fast-growing biometric access control market. According to market analysts1 , this market at $1bn in 2021, will grow to $1.4 by 2024 , twice the growth of traditional access control systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005582/en/

This booming market comes from the fact that a growing number of companies understand that for their security, they cannot rely anymore only on simple ID badges, that can be cloned (for older technologies still used by 44% of companies2 ) or simply stolen. The consequence is that it is never possible to know with certainty who is entering the premises. Biometrics , based on personal, physiological, unforgeable characteristics, provide the highest degree of certainty that the person passing the door is a genuine authorized employee. Bosch Building Technologies offers a software solution that manages different Bosch security subsystems like access control, video surveillance, fire alarm, public address and intrusion systems on one single platform, the Bosch Building Integration System (BIS) . This robust and reliable security and life safety system is proven by over 3000 installations integrating 10 million detectors worldwide.

In order to add a biometric layer to BIS, Bosch has selected IDEMIA’s terminals: IDEMIA is the market leader of biometrics for access control with more than 25 year’s experience in that domain, and hundreds of thousands of terminals successfully deployed for a great variety of industries, throughout the world.

Bosch will offer IDEMIA’s flagship contactless biometric terminals:

  • MorphoWaveTM , the only terminal in the world capable of scanning and verifying 4 fingerprints in less than 1 second through a quick, simple and fully touchless wave movement of the hand,
  • VisionPass the most advanced facial recognition terminal combining 2D, 3D and infrared cameras with IDEMIA’s leading facial algorithms.

Both terminals combine high biometric accuracy, speed and convenience with a fully touchless user experience. They operate efficiently with sanitary masks and are therefore well adapted for Covid-prevention policies. IDEMIA terminals are already integrated with the BIS platform and with most gates and turnstile vendors. This will greatly facilitate deployments in Bosch specific markets with a focus on commercial buildings, industrial and logistics sites, government premises and airports/seaports.

Bosch stands for quality and reliability. We want to offer innovative and fascinating solutions, as our slogan 'invented for life' states. When our customers are going to deploy biometric terminals for their security, they will be installed for years so we want to offer them the best option”, explains Gregor Schlechtriem, Senior Vice President Bosch Building Technologies Business Unit Access & Intrusion . “Idemia is therefore for us the right partner because of their technology expertise and field-proven quality and performances”, Schlechtriem continues.

“We are delighted to start this global partnership with Bosch”, commented Yves Portalier, EVP Biometric Devices and Automotive at IDEMIA . “The combination of our biometric devices with the BIS platform will be a strong offering for companies looking for a high level of security and user convenience”.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

1 In particular leading market analysis firm OMDIA
2 According to a ASIS International 2019 survey

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye